Articles By Jack Cush, MD
EULAR 2017 – Day 2 Highlights
The heat was on at EULAR 2017 for busy presenters and attendees navigating the 104F degree temperatures at the indoor/outdoor IFEMA Convention center in Madrid.Day 2 (Thursday) were big days for gout, drug safety, psoriatic arthritis and spondyloarthritis.
Read Article
EULAR 2017 – Day 1 Highlights
The Annual EULAR Congress kicked off this afternoon in Madrid with a number of new sessions devoted to important topics.
Read Article
Wearable Technologies Coming of Age
The first day of EULAR 2017 highlighted a symposium focus on the advances in wearable technologies. Several lectures updated attendees with the state of wearables in society and their implications on public health, fitness, weight loss and clinical trials.
Read Article
Lancet Launches EULAR 2017 and "A Platinum Age of Rheumatology"
The current Lancet edition for 10 June 2017 is a rheumatology rich collection.
Read Article
Mixed Results with Combination Therapy in Gout
Lesinurad, a selective URAT-1 inhibitor has been approved for coadministration with a urate-lowering therapy (ULT) in patients with gout for nearly a year. The CRYSTAL study was one of the studies that lead to FDA approval.
Read Article
Supreme Court Decision Favors Earlier Biosimilar Adoption
On Monday June 11th, the US Supreme Court unanimously ruled that biosimilar manufacturers can bring their drugs to market faster by eliminating the provision that the biosimar manufacturer had to give the innovator company 180 days notice before launching the new biosimilar.
Read Article
FDA Approves Abatacept for Pediatric Use
Subcutaneous (SC) abatacept (Orencia) is now available for use in patients 2 years of age and older with moderately to severely active polyarticular Juvenile Idiopathic (JIA) according to Bristol-Myers Squibb.
Read Article
The Retiring Rheumatologist
Just last week, I went to a doctor’s retirement party. It was festive, with honors and ribbing for the lucky one, but there was an asterisk to his milestone. Retirement was not anticipated or planned for. What is your retirement plan?
Read Article
The RheumNow Week in Review – 9 June 2017
Dr. Jack Cush reviews the news and reports of interest from RheumNow in the last week:
Read Article
FDA Requests Removal of OPANA-ER from the Market
The U.S. Food and Drug Administration has asked Endo International to withdraw Opana ER from the market, stating that benefits no longer outweigh its risks of this long-acting opioid.
Read Article
